Mesothelioma Stratified Therapy (MiST)

Inter-patient genomic heterogeneity underpins the variations in response to treatment with anti-cancer therapy. Some patients respond (often a minority), others do not. Presently, we are lacking knowledge to explain why these differences exist for drug treatments. We hypothesise that recurrent genomic features of mesothelioma may under-pin responsiveness to therapy. By employing a genome wide based approach to profile mesotheliomas of from patients entering the MiST trial, we aim to decipher molecular correlates of drug sensitivity and de novo or acquired resistance. This new knowledge may either facilitate future refinement of molecular stratification to underpin randomised clinical trials, or support novel research strategies (bedside to bench) to develop more effective treatments.